| Source: |
| Type: |
| Synergy — Interaction in which two or more agents, treatments, or biological interventions produce a combined effect greater than would be expected from their individual effects. In pharmacology and cancer research, synergy commonly refers to enhanced therapeutic efficacy when a compound is combined with chemotherapy, radiation, targeted therapy, or another bioactive agent. Typical modulation in cancer: ↑ synergy is generally favorable when it increases tumor-cell killing, suppresses proliferation, enhances apoptosis or ferroptosis, or improves sensitivity to anticancer therapy. Synergy should be distinguished from simple additive effects and ideally supported by quantitative combination analysis such as combination index, Bliss independence, Loewe additivity, or related methods. Typical modulation in Alzheimer’s disease: Context-dependent. Synergy may describe enhanced neuroprotective, anti-inflammatory, antioxidant, or cognitive effects produced by combinations of compounds or treatments, but it is not a disease-specific molecular pathway. |
| 8384- | LT, | Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors |
| - | Review, | GC, | NA |
| 8386- | LT, | Luteolin induces apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia cell by regulating the PI3K/AKT signaling pathway |
| - | in-vitro, | ALL, | SUP-B15 |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 3982- | Lut, | Zeax, | Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined |
| - | Trial, | AD, | NA |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
| 3285- | Lyco, | Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study |
| - | in-vitro, | Nor, | NA |
| 8414- | Lyco, | Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8413- | Lyco, | VitE, | Dietary Lycopene Supplementation Improves Cognitive Performances in Tau Transgenic Mice Expressing P301L Mutation via Inhibiting Oxidative Stress and Tau Hyperphosphorylation |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | BPH, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4798- | Lyco, | Enhancing Anticancer Treatment Efficacy With Lycopene: A Comprehensive Review of Clinical and Preclinical Evidence |
| - | Review, | Var, | NA |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 1715- | Lyco, | Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence |
| - | Review, | Var, | NA |
| 8734- | M-Blu, | From Mitochondrial Function to Neuroprotection – An Emerging Role for Methylene Blue |
| - | Review, | AD, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 8574- | Matr, | Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration |
| - | in-vitro, | Lung, | A549 | - | ex-vivo, | HCC, | SMMC-7721 cell |
| 8538- | Matr, | Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | ex-vivo, | BC, | MDA-MB-231 |
| 8527- | Matr, | Matrine Promotes Human Myeloid Leukemia Cells Apoptosis Through Warburg Effect Mediated by Hexokinase 2 |
| - | in-vitro, | AML, | K562 |
| 8544- | Matr, | Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential |
| - | Review, | BC, | NA |
| 8545- | Matr, | Matrine enhances RLS3-induced ferroptosis at non-toxic doses in acute myeloid leukemia cells with MLL rearrangement |
| - | in-vitro, | AML, | MV411 | - | in-vitro, | ALL, | MOLM-13 |
| 8934- | MBS, | MeJa, | Increased antioxidant activity and polyphenol metabolites in methyl jasmonate treated mung bean (Vigna radiata) sprouts |
| - | in-vitro, | Nor, | NA |
| 8929- | MBS, | Selenium Biofortification Enhances Functional Bioactive Components and Nutritional Quality of Edible Mung Bean Sprouts During Germination |
| - | in-vitro, | AD, | NA |
| 8629- | MBZ, | Repurposing the antihelmintic mebendazole as a hedgehog inhibitor |
| - | in-vitro, | Nor, | NIH-3T3 | - | vitro+vivo, | GBM, | GL-15 | - | in-vitro, | GC, | DAOY |
| 8631- | MBZ, | BEV, | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer |
| - | Trial, | CRC, | NA |
| 8636- | MBZ, | Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer |
| - | in-vivo, | Ovarian, | SKOV3 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-231 |
| 8641- | MBZ, | ONC201, | The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma |
| - | in-vitro, | GBM, | NA |
| 8654- | MBZ, | SUL, | Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model |
| - | in-vivo, | Colon, | HT-29 | - | in-vitro, | Colon, | SW48 |
| 8650- | MBZ, | Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial Cells |
| - | in-vitro, | Var, | NA |
| 8648- | MBZ, | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| - | Review, | Var, | NA |
| 8644- | MBZ, | The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer |
| - | vitro+vivo, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 |
| 8786- | mCHEMO, | Metronomic chemotherapy in cancer treatment: new wine in an old bottle |
| - | Review, | Var, | NA |
| 8787- | mCHEMO, | Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy |
| - | Review, | Var, | NA |
| 8788- | mCHEMO, | Metronomic Chemotherapy: A Novel Approach in Cancer Treatment |
| - | Review, | Var, | NA |
| 8789- | mCHEMO, | Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal |
| - | Review, | Var, | NA |
| 8817- | MCP, | CPT-11, | Newly Obtained Apple Pectin as an Adjunct to Irinotecan Therapy of Colorectal Cancer Reducing E. coli Adherence and β-Glucuronidase Activity |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | Caco-2 |
| 8620- | MCT, | Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review |
| - | Review, | Nor, | NA |
| 8725- | MeJa, | Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice |
| - | vitro+vivo, | HCC, | HCCLM3 | - | in-vitro, | Liver, | Bel-7402 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | HCC, | SMMC-7721 cell |
| 8757- | MeSA, | Methylseleninic acid (MSA) inhibits 17β-estradiol-induced cell growth in breast cancer T47D cells via enhancement of the antioxidative thioredoxin/ thioredoxin reductase system |
| - | in-vitro, | BC, | T47D |
| 8754- | MeSA, | Thioredoxin reductase 1 ablation sensitizes colon cancer cells to methylseleninate-mediated cytotoxicity |
| - | in-vitro, | CRC, | RKO |
| 8764- | MeSA, | Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition |
| - | in-vitro, | Lung, | A549 |
| 8707- | MET, | Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8562- | MET, | Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma |
| - | in-vitro, | Lung, | NA |
| 2379- | MET, | Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | BC, | UMUC3 |
| 2387- | MET, | GEM, | Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis |
| - | in-vitro, | CCA, | HCC9810 |
| 1043- | MET, | immuno, | Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy |
| - | in-vitro, | Var, | NA |
| 5800- | MET, | Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect |
| - | Review, | Var, | NA |
| 6936- | MF, | Ex, | Pulsed electromagnetic field with or without exercise therapy in the treatment of benign prostatic hyperplasia |
| - | Trial, | BPH, | NA |
| - | in-vitro, | AML, | THP1 | - | in-vitro, | NA, | PC12 | - | in-vivo, | Cerv, | HeLa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1849 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid